ALX Oncology Holdings Inc. Common Stock vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| ALXO | JNJ | |
|---|---|---|
| Market Cap | $272.41 million | $632.29 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | $-80,890,000 | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| ALXO | JNJ | |
|---|---|---|
| P/E Ratio | — | 31.45 |
| Price / Book | 2.00 | 7.44 |
| Price / Sales | — | 6.46 |
ALXO leads on 1 of 1 valuation factors.
Profitability
| ALXO | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | -59.40% | 24.76% |
JNJ leads on 1 of 1 profitability factors.
Dividend
| ALXO | JNJ | |
|---|---|---|
| Dividend Yield | — | 1.98% |
| Payout Ratio | — | 62.18 |
ALXO and JNJ split the dividend factors evenly.
Risk & Sentiment
| ALXO | JNJ | |
|---|---|---|
| Short Interest | 0.00% | 0.67% |
ALXO leads on 1 of 1 risk & sentiment factors.
Dig deeper: ALXO overview, ALXO financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.